Diabetic nephropathy Market By Drugs Class (Angiotensin-converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blocker, Diuretics, Renin Inhibitor, Others), By Type (Type-1 Diabetes, Type-2 Diabetes), By Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2022-2031

Diabetic nephropathy Market

Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.

Hypertension or high blood pressure and high cholesterol is a complication of diabetes that is believed to contribute directly to diabetic nephropathy. Therefore, anti-hypertensive drug and anti-hyperlipidemic drug is used to treat diabetic kidney diseases.

Growth of the diabetic nephropathy market is majorly driven by rise in geriatric population, surge in number of patients suffering from diabetes, chronic renal disease, atherosclerosis, and hypertension. Globally, the diabetic nephropathy market is witnessing significant growth, owing to increase in prevalence of diabetes and obesity in different regions of the world. In addition, rise in R&D investments in drug discovery and development and rise in awareness regarding diabetes and kidney-related disorders.

For instance, according to latest reports of the Indian Council of Medical Research, there were around 150% increment in diabetes cases in India in 2021. For instance, according to the International Diabetes Federation (IDF) Atlas Tenth edition 2021, approximately 537 million adults (20–79 years) are living with diabetes. More than 1.2 million children and adolescents (0–19 years) are living with type 1 diabetes, 541 million adults are at increased risk of developing type 2 diabetes, and 1 in 6 live births (21 million) are affected by diabetes during pregnancy.

For instance, according to the 9th edition of International Diabetes Federation, 463 million people are currently affected by diabetes globally, and it is expected to increase to 642 million by 2040.

Thus, above-mentioned factors are anticipated to fuel adoption of medicinal products against diabetic nephropathy disease. Furthermore, the market is highly competitive in nature, with major players focusing on creating awareness regarding diabetic nephropathy. Major players in the diabetic nephropathy market host exhibition and seminars to display and promote use of diabetic nephropathy for diverse medical applications.

In addition, discovery and development; launch of various products; and strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, in 2021, ASTRAZENECA got the approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to the strict government regulations on the quality of ingredient and excipients that are used in it. . Strict regulatory rules regarding selling and lengthy drug approval times also hamper the market growth.

On the contrary, surge in healthcare investments in public as well as private sectors, increase in patient population, and unmet medical demands in developing economies in mostly countries are anticipated to open new avenues for expansion of the diabetic nephropathy market during the forecast period.

By drug class type, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor to the market, with $567.95 million in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension, and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR of 7.4% during the forecast period, owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones, and diabetic nephropathy.

On the basis of types, the type-2 diabetes segment generated maximum revenue in 2021, accounting for $1,465.61 million, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR of 6.4% during the forecast period.

On the basis of distribution channel, the drug stores & retail pharmacy segment was the highest revenue contributor to the market, with $ 992.24 million in 2021, and is estimated to reach $1,831.91 million by 2031, with a CAGR of 6.3%. The hospital pharmacy segment is estimated to reach $946.30 million by 2031, at a significant CAGR of 4.6% during the forecast period, owing to increase in population suffering from diabetes and geriatric population. Depending on region, North America generated maximum revenue in 2021, accounting for $ 807.50 million, owing to increase in number of patient admissions and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR of 7.3% during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.

Key findings of the study

By drug class type, the angiotensin-converting enzyme inhibitors segment held the largest share in the diabetic nephropathy market in 2021.

By type, the type-2 diabetes segment held the largest share in the diabetic nephropathy market in 2021, and is expected to remain dominant during the forecast period.

On the basis of distribution channel, the drug stores & retail pharmacy segment held the largest market share in 2021.

On the basis of region, the hospitals segment held the largest market share in 2021, and is expected to remain dominant during the forecast period.

Overview

Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in people with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD), globally. Diabetic nephropathy is also defined by elevated urine albumin excretion or reduced glomerular filtration rate (GFR), or both. It is a serious complication that occurs in 20–40% of all diabetic patients.

Diabetic nephropathy is usually diagnosed during routine testing, which is a part of the diabetes management. Routine test used for diagnosis of diabetic nephropathy include urinary albumin test, albumin/creatinine ratio, and glomerular filtration rate (GFR) and other special tests such as imaging tests (CT scanning, MRI) and Kidney biopsy.

Treatments of diabetic nephropathy are very necessary for patients. The first step in treating diabetic nephropathy is to treat and control diabetes and high blood pressure (hypertension). This includes diet, lifestyle changes, exercise, prescription medications, blood pressure control medicine, blood sugar control medicine, G-Protein Coupled Receptors (GPCR), and antioxidant inflammation modulators medicine. Furthermore, kidney dialysis, transplant, and symptom management treatment are also used for advanced diabetic kidney diseases. The diabetic nephropathy market is growing at rapid rate. Major factors driving growth of the diabetic nephropathy market include increase in geriatric population suffering from diabetes, increase in diabetic population, and rise in incidences of various kidney diseases. For instance, according to the Journal of Nutrition and Metabolism, in a survey at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, the incidence rate of diabetic nephropathy was 14 (95% CI 10.8–17.7) cases per 10,000 patients. In addition, 63 (13.6%) diabetes mellitus (DM) patients developed diabetic nephropathy. Type 2 DM patients who had coronary heart diseases and anemia were at higher hazard of developing diabetic nephropathy. Hence, such factors propel the market growth.

For instance, according to the National Diabetes Statistics Latest Report, 37.3 million people had diabetes (11.3% of the US population) in which 28.7 million people, including 28.5 million adults were diagnosed and 8.5 million people (23.0% of adults are undiagnosed) were undiagnosed in the U.S from 2017 to 2020.

Moreover, surge in diabetes and chronic kidney diseases leads to increase in number of diabetic nephropathies, which further require anti-diabetic nephropathy medicines, thus propelling adoption of anti-diabetic nephropathy medicine. Angiotensin-converting enzyme inhibitors have become more popular among products of diabetic nephropathy. Type-2 diabetes is the most trending diabetic nephropathy that draws attention of customers, fueling growth of the diabetic nephropathy market. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, AstraZeneca Plc. got approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, unfavorable reimbursements as well as complications such as the market growth is limited by stricter regulatory standards and lengthy drug approval times. The market growth of the diabetic nephropathy is also restrained, owing to lack of comprehensive therapeutic therapy for diabetic nephropathy.

Furthermore, healthcare business is predicted to witness growth, owing to rise in prevalence of diabetes and obesity, increase in R&D investments in drug discovery & development, and rise in awareness regarding diabetes and kidney-related disorders. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The diabetic nephropathy market is segmented on the basis of drug class, type, distribution channel, and region. On the basis of drug class, the market is classified into angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blocker, diuretics, renin inhibitor, and others. By type, the market is segregated into type-1 diabetes and type-2 diabetes. Depending on distribution channel, it is fragmented into hospital pharmacy, online providers, and drug stores & retail pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA)

Major players profiled in the report are Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer Ag, Eli Lilly and Company, Merck & Co, Inc., Novartis Ag, Pfizer Inc., Reata Pharmaceuticals, Inc., and Sanofi.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic nephropathy market analysis from 2021 to 2031 to identify the prevailing diabetic nephropathy market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the diabetic nephropathy market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global diabetic nephropathy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ Reata Pharmaceutical

Scope of Diabetic nephropathy Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Surge in number of geriatric populations suffering from diabetes and rise in prevalence of chronic kidney diseases, obesity, and hypertension

3.4.1.2. Rise in awareness regarding diabetic nephropathy and increase in diagnostic tests

3.4.2. Restraints

3.4.2.1. Strict regulatory rules and lengthy drug approval times

3.4.3. Opportunities

3.4.3.1. Rise in use of combination therapy for diabetic nephropathy

3.4.3.2. Increase in R&D investments in drug discovery and development

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Angiotensin-converting Enzyme Inhibitors

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Angiotensin Receptor Blockers

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Calcium Channel Blocker

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

4.5. Diuretics

4.5.1. Key market trends, growth factors and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market share analysis by country

4.6. Renin Inhibitor

4.6.1. Key market trends, growth factors and opportunities

4.6.2. Market size and forecast, by region

4.6.3. Market share analysis by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities

4.7.2. Market size and forecast, by region

4.7.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Type-1 Diabetes

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Type-2 Diabetes

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacy

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Online Providers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Drug Stores and Retail Pharmacy

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Drugs Class

7.2.3. Market size and forecast, by Type

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Drugs Class

7.2.5.1.3. Market size and forecast, by Type

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Drugs Class

7.2.5.2.3. Market size and forecast, by Type

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Drugs Class

7.2.5.3.3. Market size and forecast, by Type

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Drugs Class

7.3.3. Market size and forecast, by Type

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Drugs Class

7.3.5.1.3. Market size and forecast, by Type

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Drugs Class

7.3.5.2.3. Market size and forecast, by Type

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. U.K.

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Drugs Class

7.3.5.3.3. Market size and forecast, by Type

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Drugs Class

7.3.5.4.3. Market size and forecast, by Type

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Drugs Class

7.3.5.5.3. Market size and forecast, by Type

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Drugs Class

7.3.5.6.3. Market size and forecast, by Type

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Drugs Class

7.4.3. Market size and forecast, by Type

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Drugs Class

7.4.5.1.3. Market size and forecast, by Type

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Drugs Class

7.4.5.2.3. Market size and forecast, by Type

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Drugs Class

7.4.5.3.3. Market size and forecast, by Type

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Drugs Class

7.4.5.4.3. Market size and forecast, by Type

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Drugs Class

7.4.5.5.3. Market size and forecast, by Type

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Drugs Class

7.4.5.6.3. Market size and forecast, by Type

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Drugs Class

7.5.3. Market size and forecast, by Type

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Drugs Class

7.5.5.1.3. Market size and forecast, by Type

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Drugs Class

7.5.5.2.3. Market size and forecast, by Type

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Drugs Class

7.5.5.3.3. Market size and forecast, by Type

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Drugs Class

7.5.5.4.3. Market size and forecast, by Type

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. AbbVie Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. Abbott Laboratories

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Bayer AG

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.4. Eli Lilly and Company

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.5. Merck & Co

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.6. Astrazenica Plc

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.7. Novartis AG

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Pfizer Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Reata Pharmaceuticals

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Sanofi

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 02. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2021-2031 ($MILLION)

TABLE 03. DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2021-2031 ($MILLION)

TABLE 04. DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2021-2031 ($MILLION)

TABLE 05. DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY REGION, 2021-2031 ($MILLION)

TABLE 06. DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)

TABLE 07. DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 08. GLOBAL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 09. DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY REGION, 2021-2031 ($MILLION)

TABLE 10. DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY REGION, 2021-2031 ($MILLION)

TABLE 11. GLOBAL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 12. DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 13. DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)

TABLE 14. DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)

TABLE 15. DIABETIC NEPHROPATHY MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 16. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 17. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 18. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 19. NORTH AMERICA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. U.S. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 21. U.S. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 22. U.S. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 23. CANADA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 24. CANADA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 25. CANADA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 26. MEXICO DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 27. MEXICO DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 28. MEXICO DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 29. EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 30. EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 31. EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 32. EUROPE DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 33. GERMANY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 34. GERMANY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 35. GERMANY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 36. FRANCE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 37. FRANCE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 38. FRANCE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 39. U.K. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 40. U.K. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 41. U.K. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 42. ITALY DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 43. ITALY DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 44. ITALY DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 45. SPAIN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 46. SPAIN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 47. SPAIN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 48. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 49. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 50. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 53. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 54. ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 55. JAPAN DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 56. JAPAN DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. JAPAN DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 58. CHINA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 59. CHINA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. CHINA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 61. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 62. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. AUSTRALIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 64. INDIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 65. INDIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 66. INDIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 67. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 68. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 69. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 72. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 73. LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 74. LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 75. LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 76. LAMEA DIABETIC NEPHROPATHY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 77. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 78. BRAZIL DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 79. BRAZIL DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 80. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 81. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 82. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 83. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 84. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 85. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 86. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021-2031 ($MILLION)

TABLE 87. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 88. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)

TABLE 89. ABBVIE INC.: KEY EXECUTIVES

TABLE 90. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 91. ABBVIE INC.: PRODUCT SEGMENTS

TABLE 92. ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 93. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 94. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 95. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 96. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 97. BAYER AG: KEY EXECUTIVES

TABLE 98. BAYER AG: COMPANY SNAPSHOT

TABLE 99. BAYER AG: PRODUCT SEGMENTS

TABLE 100. BAYER AG: PRODUCT PORTFOLIO

TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES

TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS

TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 105. MERCK & CO: KEY EXECUTIVES

TABLE 106. MERCK & CO: COMPANY SNAPSHOT

TABLE 107. MERCK & CO: PRODUCT SEGMENTS

TABLE 108. MERCK & CO: PRODUCT PORTFOLIO

TABLE 109. ASTRAZENICA PLC: KEY EXECUTIVES

TABLE 110. ASTRAZENICA PLC: COMPANY SNAPSHOT

TABLE 111. ASTRAZENICA PLC: PRODUCT SEGMENTS

TABLE 112. ASTRAZENICA PLC: PRODUCT PORTFOLIO

TABLE 113. NOVARTIS AG: KEY EXECUTIVES

TABLE 114. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 115. NOVARTIS AG: PRODUCT SEGMENTS

TABLE 116. NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 117. PFIZER INC.: KEY EXECUTIVES

TABLE 118. PFIZER INC.: COMPANY SNAPSHOT

TABLE 119. PFIZER INC.: PRODUCT SEGMENTS

TABLE 120. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 121. REATA PHARMACEUTICALS: KEY EXECUTIVES

TABLE 122. REATA PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 123. REATA PHARMACEUTICALS: SERVICE SEGMENTS

TABLE 124. REATA PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 125. SANOFI: KEY EXECUTIVES

TABLE 126. SANOFI: COMPANY SNAPSHOT

TABLE 127. SANOFI: PRODUCT SEGMENTS

TABLE 128. SANOFI: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. DIABETIC NEPHROPATHY MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF DIABETIC NEPHROPATHY MARKET,2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC NEPHROPATHY MARKET (2022-2031)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW INTENSITY OF RIVALRY

FIGURE 08. LOW BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL DIABETIC NEPHROPATHY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. DIABETIC NEPHROPATHY MARKET, BY DRUGS CLASS, 2021(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY COUNTRY 2021 AND 2031(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY 2021 AND 2031(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DIURETICS, BY COUNTRY 2021 AND 2031(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR RENIN INHIBITOR, BY COUNTRY 2021 AND 2031(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 17. DIABETIC NEPHROPATHY MARKET, BY TYPE, 2021(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-1 DIABETES, BY COUNTRY 2021 AND 2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR TYPE-2 DIABETES, BY COUNTRY 2021 AND 2031(%)

FIGURE 20. DIABETIC NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2021(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2021 AND 2031(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIABETIC NEPHROPATHY MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2021 AND 2031(%)

FIGURE 24. DIABETIC NEPHROPATHY MARKET BY REGION, 2021(%)

FIGURE 25. U.S. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 26. CANADA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 27. MEXICO DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 28. GERMANY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 29. FRANCE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 30. U.K. DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 31. ITALY DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 32. SPAIN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 33. REST OF EUROPE DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 34. JAPAN DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 35. CHINA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 36. AUSTRALIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 37. INDIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 38. SOUTH KOREA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 39. REST OF ASIA-PACIFIC DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 40. BRAZIL DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 41. SAUDI ARABIA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 42. SOUTH AFRICA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 43. REST OF LAMEA DIABETIC NEPHROPATHY MARKET, 2021-2031 ($MILLION)

FIGURE 44. TOP WINNING STRATEGIES, BY YEAR

FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 48. COMPETITIVE DASHBOARD

FIGURE 49. COMPETITIVE HEATMAP: DIABETIC NEPHROPATHY MARKET

FIGURE 50. TOP PLAYER POSITIONING, 2021

FIGURE 51. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 52. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 53. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)

FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 66. REATA PHARMACEUTICALS: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)

FIGURE 67. REATA PHARMACEUTICALS: NET REVENUE, 2020-2022 ($MILLION